Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
9.31
Dollar change
+0.97
Percentage change
11.63
%
IndexRUT P/E- EPS (ttm)-1.26 Insider Own33.54% Shs Outstand64.58M Perf Week36.71%
Market Cap602.17M Forward P/E- EPS next Y-1.41 Insider Trans-1.90% Shs Float42.98M Perf Month27.01%
Income-91.06M PEG- EPS next Q-0.34 Inst Own76.42% Short Float6.25% Perf Quarter78.35%
Sales0.00M P/S- EPS this Y-5.52% Inst Trans32.53% Short Ratio2.48 Perf Half Y51.88%
Book/sh3.66 P/B2.54 EPS next Y-5.49% ROA-33.23% Short Interest2.69M Perf Year15.94%
Cash/sh3.72 P/C2.50 EPS next 5Y- ROE-34.73% 52W Range3.26 - 9.16 Perf YTD43.45%
Dividend Est.- P/FCF- EPS past 5Y-12.40% ROI-38.47% 52W High1.64% Beta-0.35
Dividend TTM- Quick Ratio27.85 Sales past 5Y-20.00% Gross Margin- 52W Low185.58% ATR (14)0.67
Dividend Ex-Date- Current Ratio27.85 EPS Y/Y TTM20.62% Oper. Margin0.00% RSI (14)71.25 Volatility10.56% 8.63%
Employees66 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.57 Target Price13.58
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q2.53% Payout- Rel Volume1.50 Prev Close8.34
Sales Surprise- EPS Surprise13.42% Sales Q/Q- EarningsMay 13 BMO Avg Volume1.08M Price9.31
SMA2027.25% SMA5041.11% SMA20055.73% Trades Volume1,621,781 Change11.63%
Date Action Analyst Rating Change Price Target Change
Jun-22-23Initiated Mizuho Buy $16
Jun-07-23Initiated Jefferies Buy $18
May-31-23Initiated ROTH MKM Buy $23
May-08-23Initiated BMO Capital Markets Outperform $18
Feb-14-23Initiated JMP Securities Mkt Outperform $17
Feb-07-23Initiated UBS Buy $19
Sep-12-22Initiated H.C. Wainwright Neutral $6
Sep-14-21Resumed Goldman Buy $21
Mar-02-21Initiated JP Morgan Overweight $32
Mar-02-21Initiated Goldman Buy $29
Jun-21-24 06:30PM
Jun-19-24 01:27PM
Jun-04-24 09:55AM
Jun-03-24 04:10PM
May-30-24 08:05AM
04:05PM Loading…
May-17-24 04:05PM
May-13-24 01:53PM
09:32AM
08:05AM
May-08-24 04:05PM
May-07-24 04:05PM
May-03-24 04:05PM
Apr-29-24 04:05PM
Apr-10-24 04:05PM
Mar-14-24 04:05PM
04:05PM Loading…
Mar-11-24 04:05PM
Mar-07-24 04:05PM
Feb-27-24 04:05PM
Feb-07-24 04:05PM
08:05AM
Feb-02-24 04:05PM
Jan-04-24 04:05PM
Jan-03-24 04:05PM
Nov-29-23 04:05PM
Nov-27-23 04:05PM
Nov-14-23 12:16PM
08:05AM
Nov-13-23 08:05AM
Nov-09-23 08:05AM
Nov-03-23 04:05PM
04:05PM Loading…
Nov-02-23 04:05PM
Oct-19-23 04:05PM
Oct-16-23 08:05AM
Oct-03-23 04:05PM
Sep-06-23 04:05PM
Sep-05-23 04:05PM
Aug-08-23 04:15PM
04:05PM
Aug-03-23 06:00PM
05:05PM
Jul-28-23 07:01PM
Jul-18-23 04:05PM
Jul-05-23 04:05PM
Jun-26-23 04:05PM
Jun-06-23 04:30PM
Jun-02-23 04:05PM
May-28-23 09:45AM
May-25-23 05:05PM
May-24-23 04:05PM
May-22-23 04:05PM
May-15-23 08:05AM
May-09-23 04:05PM
May-03-23 04:05PM
Apr-25-23 12:00PM
Mar-30-23 02:28PM
Mar-27-23 04:05PM
08:05AM
Mar-08-23 05:26AM
Mar-02-23 04:05PM
Feb-26-23 10:51AM
Feb-08-23 12:00PM
Feb-02-23 04:05PM
Jan-12-23 04:05PM
Jan-05-23 04:05PM
Dec-23-22 04:05PM
Dec-20-22 07:40PM
08:05AM
Dec-19-22 04:31PM
Dec-01-22 04:05PM
Nov-16-22 09:31AM
Nov-09-22 04:05PM
Nov-04-22 08:05AM
Oct-26-22 04:05PM
Oct-12-22 05:26AM
Oct-11-22 04:05PM
Sep-29-22 06:03AM
Sep-21-22 05:33AM
Sep-07-22 04:05PM
Aug-19-22 06:50AM
Aug-12-22 08:00AM
Aug-08-22 04:05PM
Jul-27-22 04:05PM
Jul-22-22 12:00PM
Jun-22-22 04:05PM
Jun-09-22 06:31AM
Jun-08-22 04:05PM
Jun-01-22 04:05PM
May-16-22 04:05PM
Apr-05-22 01:38PM
Apr-04-22 04:05PM
Mar-21-22 04:05PM
Mar-03-22 04:05PM
Feb-28-22 04:05PM
Feb-04-22 11:37AM
Feb-02-22 05:38PM
Jan-06-22 07:05AM
Jan-03-22 04:05PM
Nov-15-21 04:05PM
Nov-12-21 07:05AM
Nov-10-21 07:17AM
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vivo Opportunity, LLC10% OwnerApr 03 '24Sale6.20138,066856,009268,573Apr 03 08:47 PM
Vivo Opportunity, LLC10% OwnerApr 02 '24Sale6.65101,480674,842272,722Apr 03 08:47 PM
Vivo Opportunity, LLC10% OwnerApr 01 '24Sale6.99181,1171,266,008275,772Apr 03 08:47 PM